ARTICLE | Clinical News
Selecta's gene therapy improves survival in MMA mice
May 19, 2017 7:11 PM UTC
Selecta Biosciences Inc. (NASDAQ:SELB) said its Anc80-synMUT gene therapy corrected methylmalonyl CoA mutase (MUT) mutations and led to survival benefits in mouse models of methylmalonic acidemia (MMA)...